You are here

Article info

Article menu
Basic and translational research
Extended report
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

Authors

  1. Correspondence to David L Boyle, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego School of Medicine, San Diego, CA 92093, USA; dboyle{at}ucsd.edu
View Full Text

Citation

Boyle DL, Soma K, Hodge J, et al
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
Annals of the Rheumatic Diseases 2015;74:1311-1316.

Publication history

  • Received June 2, 2014
  • Revised September 16, 2014
  • Accepted October 24, 2014
  • First published November 14, 2014.
Online issue publication 
November 02, 2019

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/